![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company developing novel small molecules for the treatment of inflammatory diseases, including treatments for asthma, allergies, and arthritis, and also has the rights to a patented small molecule with anti-tumor activity. IZP's Institutional investors include Royal Bank, Royal Trust, Biotech Investments Ltd., Goldman Sachs, Business Development Bank of Canada, Sofinov, and Working Opportunity Fund. For more information visit: inflazyme.com | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |